Amicus Therapeutics (FOLD) Stock Rating Upgraded by BidaskClub

Amicus Therapeutics (NASDAQ:FOLD) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

Other research analysts have also recently issued reports about the company. Leerink Swann reaffirmed a “buy” rating and set a $20.00 price objective (up from $17.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Bank of America upped their price objective on Amicus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 4th. Chardan Capital reaffirmed a “buy” rating and set a $18.50 price objective (up from $16.50) on shares of Amicus Therapeutics in a research report on Thursday, October 5th. Zacks Investment Research raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a report on Tuesday, October 10th. Finally, Goldman Sachs Group reissued a “neutral” rating and issued a $17.00 target price on shares of Amicus Therapeutics in a report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $17.81.

Amicus Therapeutics (NASDAQ FOLD) opened at $14.16 on Thursday. Amicus Therapeutics has a 1 year low of $4.59 and a 1 year high of $16.60. The company has a current ratio of 6.32, a quick ratio of 6.22 and a debt-to-equity ratio of 0.39.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). The business had revenue of $10.90 million for the quarter, compared to analyst estimates of $9.02 million. Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The company’s revenue was up 419.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.33) earnings per share. sell-side analysts predict that Amicus Therapeutics will post -1.56 earnings per share for the current fiscal year.

In other news, insider Jay Barth sold 5,000 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $13.59, for a total value of $67,950.00. Following the completion of the sale, the insider now directly owns 69,184 shares of the company’s stock, valued at approximately $940,210.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO John F. Crowley sold 65,581 shares of the business’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $13.51, for a total value of $885,999.31. Following the completion of the sale, the chief executive officer now directly owns 393,076 shares of the company’s stock, valued at $5,310,456.76. The disclosure for this sale can be found here. Insiders sold a total of 758,224 shares of company stock valued at $10,785,546 over the last three months. Company insiders own 3.40% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Strs Ohio purchased a new stake in Amicus Therapeutics during the 3rd quarter valued at approximately $102,000. Teacher Retirement System of Texas raised its stake in Amicus Therapeutics by 1.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 169 shares during the last quarter. Tudor Investment Corp ET AL purchased a new stake in Amicus Therapeutics during the 2nd quarter valued at approximately $124,000. Aperio Group LLC raised its stake in shares of Amicus Therapeutics by 13.5% during the 2nd quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 1,663 shares in the last quarter. Finally, Zacks Investment Management purchased a new position in shares of Amicus Therapeutics during the 2nd quarter worth approximately $145,000.

ILLEGAL ACTIVITY NOTICE: “Amicus Therapeutics (FOLD) Stock Rating Upgraded by BidaskClub” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/12/23/amicus-therapeutics-fold-stock-rating-upgraded-by-bidaskclub.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit